Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Down 38.8% in January

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 93,300 shares, a decline of 38.8% from the December 31st total of 152,400 shares. Approximately 2.1% of the company’s stock are short sold. Based on an average daily trading volume, of 111,600 shares, the short-interest ratio is currently 0.8 days.

Brainstorm Cell Therapeutics Price Performance

BCLI traded down $0.12 during trading on Thursday, hitting $1.91. The company had a trading volume of 58,172 shares, compared to its average volume of 56,493. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.89. The company has a market cap of $10.89 million, a PE ratio of -0.40 and a beta of 0.29. The business has a 50-day moving average of $1.95 and a 200-day moving average of $2.96.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.